Adjunct Faculty
Adjunct faculty typically have an academic or research appointment at another institution and contribute or collaborate with one or more School of Medicine faculty members or programs.
Adjunct rank detailsNiketa C Shah, MD
Associate Professor AdjunctDownloadHi-Res Photo
About
Copy Link
Titles
Associate Professor Adjunct
Director,Pediatric Cellular Therapy Program, Pediatric Hematology & Oncology; Director, Pediatric Bone Marrow Transplant Program
Appointments
Pediatric Hematology & Oncology
Associate Professor AdjunctPrimary
Other Departments & Organizations
- All Institutions
- Pediatric Bone Marrow Transplant Program
- Pediatric Hematology & Oncology
- Pediatric Hematology & Oncology Program
- Pediatrics
- Yale Cancer Center
Education & Training
- Pediatric Stem Cell Transplant Fellow
- Memorial Sloan Kettering Cancer Center (2010)
- Pediatric Resident
- Newark Beth Israel Medical Center (2009)
- Pediatric Hematology Oncology Fellow
- The Hospital For Sick Children, Toronto (2006)
- MD
- Seth K M School of Postgraduate Medicine and Research, Pediatrics (1997)
- MBBS
- NHL Municipal Medical College (1994)
Research
Copy Link
Overview
Medical Research Interests
Anemia, Sickle Cell; Bone Marrow Failure Disorders; Bone Marrow Transplantation; Hematology; Hematopoietic Stem Cell Transplantation; Pediatrics; Receptors, Chimeric Antigen
ORCID
0000-0001-9992-4921
Research at a Glance
Yale Co-Authors
Frequent collaborators of Niketa C Shah's published research.
Publications Timeline
A big-picture view of Niketa C Shah's research output by year.
Research Interests
Research topics Niketa C Shah is interested in exploring.
Lakshmanan Krishnamurti, MD
Aron Flagg, MD
Yanhong Deng
Jingchen Liang
Daniel Prior, MD
Farzana Pashankar, MD, MRCP, MBBS
57Publications
267Citations
Hematopoietic Stem Cell Transplantation
Anemia, Sickle Cell
Bone Marrow Transplantation
Receptors, Chimeric Antigen
Publications
2026
Long-term follow-up after mixed donor myeloid chimerism at 1 year post transplantation for sickle cell disease
Guilcher G, Dalal S, Suresh T, Yelamali A, Arora J, Aljayyousi H, Bhatia M, Haight A, Khandelwal P, Khoury R, Lafay Q, Mandava M, Nickel R, Ngwube A, Rangarajan H, Shah N, Stenger E, Yelamanchili N, Shenoy S. Long-term follow-up after mixed donor myeloid chimerism at 1 year post transplantation for sickle cell disease. Transplantation And Cellular Therapy 2026 PMID: 41690551, DOI: 10.1016/j.jtct.2026.02.012.Peer-Reviewed Original ResearchCitationsConceptsHematopoietic cell transplantationDonor myeloid chimerismSickle cell diseaseMyeloid chimerismFollow-upPost-HCTConditioning regimensCell diseaseLaboratory markersClinical outcomesHigher chimerismClinical long-term outcomeLifetime surveillanceLong-term follow-upMyeloablative conditioning regimensYears of follow-upTime to follow-upYear post-transplantationMarkers of hemolysisLong-term outcomesNorth American centersSurvivors of hematopoietic cell transplantationLaboratory markers of hemolysisCohort of childrenHemoglobin S percentageOutcomes Following Graft Failure and Second Subsequent Allogeneic Hematopoietic Cell Transplant in Patients with Sickle Cell Disease: A Multicenter Study
Rangarajan H, Stenger E, Shenkar R, Stanek J, Alzaharani M, Hsieh M, Limerick E, Darrigo L, Bonfim C, Bhatia M, Gupta A, Smith A, Mahadeo K, Page K, Olson T, Philipson B, Nickel R, Shenoy S, Chaudhury S, Lalefar N, Talano J, Waldhart J, Abusin G, Sharma A, Camacho-Bydume C, Krajewski J, Rahim M, McKinney C, Horn B, Kashif R, Milner J, Eckrich M, Kent M, Kasow K, Ngwube A, Khalid Y, John T, Akhom P, Hanna R, Khandelwal P, Shah N, Krishnamurti L, Nemecek E, Horan J, Guilcher G, Kassim A, Abraham A. Outcomes Following Graft Failure and Second Subsequent Allogeneic Hematopoietic Cell Transplant in Patients with Sickle Cell Disease: A Multicenter Study. Transplantation And Cellular Therapy 2026, 32: s18-s19. DOI: 10.1016/j.jtct.2025.12.033.Peer-Reviewed Original ResearchAltmetricConceptsAllogeneic hematopoietic cell transplantationHematopoietic cell transplantationSickle cell diseaseOverall survivalGraft failureClinical outcomesCell transplantationNO therapyUnivariate analysisFollow-upHCT groupCell diseaseHematopoietic cell transplant recipientsEvent-free survivalHistory of cerebrovascular diseaseFactors associated with outcomesMulticenter retrospective studyRed cell alloantibodiesPost-HCT complicationsRisk factors associated with outcomesIdentification of risk factorsKaplan-Meier estimatesChronic graftHost diseaseMedian ageQuality Perspective: Implementing a New Critical Procedure
Howarth E, Ritchie M, McEntee N, Shah N. Quality Perspective: Implementing a New Critical Procedure. Transplantation And Cellular Therapy 2026, 32: s514. DOI: 10.1016/j.jtct.2025.12.767.Peer-Reviewed Original ResearchConceptsAudit checklistProcess improvementImplementation of process improvementBone marrow harvesting procedureCritical suppliesQuality managementPDSA modelBone marrow harvestExpansion of servicesStaff educationAuditTeam membersMultidisciplinary teamMarrow harvestMultidisciplinary collaborationChecklistOverall qualityConsistency of performanceCollaborative efforts
2025
Impact of Abatacept Inclusive Graft-Versus-Host Disease Prophylaxis in Pediatric Stem Cell Transplantation for Hemoglobinopathy
Shah N, Ngwube A, Suresh T, Sowa A, Abraham A, Anderson E, Andreansky M, Bhatia M, Chaudhury S, Cuvelier G, Dalal J, Grimley M, Jacobsohn D, Kamani N, Krajewski J, Krishnamurti L, Saini S, Skiles J, Shenoy S. Impact of Abatacept Inclusive Graft-Versus-Host Disease Prophylaxis in Pediatric Stem Cell Transplantation for Hemoglobinopathy. Transplantation And Cellular Therapy 2025, 31: 826.e1-826.e10. PMID: 40543708, DOI: 10.1016/j.jtct.2025.06.015.Peer-Reviewed Original ResearchCitationsAltmetricConceptsGraft-versus-host diseaseChronic graft-versus-host diseaseHematopoietic cell transplantationGraft-versus-host disease prophylaxisGVHD prophylaxisAbatacept groupCell transplantationIncidence of posterior reversible encephalopathy syndromeSeverity of graft-versus-host diseasePresence of graft-versus-host diseasePosterior reversible encephalopathy syndromeAllogeneic hematopoietic cell transplantationSibling donor hematopoietic cell transplantationDonor hematopoietic cell transplantationDonor-derived hematopoiesisImmune reconstitution patternsReduced intensity conditioningEvent-free survivalGraft-versus-hostHost disease prophylaxisReversible encephalopathy syndromeSystemic immune suppressionStem cell transplantationPrimary graft rejectionPediatric stem cell transplantationComparison of Regimens Used for Allogeneic Matched Related Donor Hematopoietic Cell Transplantation for Sickle Cell Disease
Prior D, Liang J, Deng Y, Shah N, Flagg A, Krishnamurti L. Comparison of Regimens Used for Allogeneic Matched Related Donor Hematopoietic Cell Transplantation for Sickle Cell Disease. Transplantation And Cellular Therapy 2025, 31: 594.e1-594.e13. PMID: 40379050, DOI: 10.1016/j.jtct.2025.05.004.Peer-Reviewed Original ResearchCitationsAltmetricConceptsGraft-versus-host diseaseHematopoietic cell transplantationHLA-matched related donorSickle cell diseaseConditioning regimen intensityAnti-thymocyte globulinEFS ratesConditioning regimensRegimen intensityCell transplantationRate of chronic graft-versus-host diseaseRelated donorsChronic graft-versus-host diseaseHematopoietic cell transplantation regimensNon-myeloablative conditioning regimensAllogeneic hematopoietic cell transplantationCell diseaseComparison of regimensMyeloablative conditioning regimensNon-myeloablative conditioningNon-myeloablative regimensSickle cell disease patientsEvent-free survivalGraft-versus-hostAnti-thymocyteDonor, Recipient, and Parent Characteristics Associated with Poor Pediatric Sibling Hematopoietic Stem Cell Donor Pre-Donation Health-Related Quality-of-Life; Early Results of the Donorkids QL Study
Switzer G, Bruce J, Shaw B, Kuniyil V, Varni J, Butler B, Erickson C, Mussetter A, Aguayo-Hiraldo P, Anderson E, Aquino V, Boone K, Chewning J, Dahlberg A, Dvorak C, Haight A, Hoag J, Hudspeth M, Jacobsohn D, Kasow K, Kitko C, Miller H, Olson T, Pawlowska A, Prasad V, Quigg T, Scaradavou A, Shah N, Shenoy S, Silva J, Terwilliger N, Wiener L, Yanik G, Yu L, Pulsipher M. Donor, Recipient, and Parent Characteristics Associated with Poor Pediatric Sibling Hematopoietic Stem Cell Donor Pre-Donation Health-Related Quality-of-Life; Early Results of the Donorkids QL Study. Transplantation And Cellular Therapy 2025, 31: s95-s96. DOI: 10.1016/j.jtct.2025.01.151.Peer-Reviewed Original ResearchAltmetricConceptsHealth-related quality-of-lifeQuality-of-lifePoorer health-related quality-of-lifeFamily unitFamily cohesionPredictors of HRQoL.Aged 5Low parental education levelSelf-reported depressionParental demographic characteristicsParental education levelDonation processParental HRQoLPsychosocial scoresPartnership statusLow family cohesionQL studiesFamily characteristicsPsychosocial effectsHRQoLEmployment statusEducation levelHRQoL.Pre-donationInterview dataNew Beginnings: Implementing a Pediatric Hemopoietic Stem Cell and Cellular Therapy Program
Fastenau S, Dillard S, McEntee N, Centofanti D, Ramos R, Shah N. New Beginnings: Implementing a Pediatric Hemopoietic Stem Cell and Cellular Therapy Program. Transplantation And Cellular Therapy 2025, 31: s475. DOI: 10.1016/j.jtct.2025.01.745.Peer-Reviewed Original ResearchConceptsTherapy programRegistered NursesNursing care needsFull-day sessionsPost-testEvidence-based advancesTransplantation processNursing interventionsNursing careNursing staffCare needsStem cell transplantation processesEducation sessionsNursesStaff trainingEducation programsIntensive care unitTeam membersEducational conferencesSkill componentsStaffEducation staffMaximum attendanceCare unitIdentifying opportunities
2024
Incidence and risk factors of pain crisis after hematopoietic cell transplantation for sickle cell disease
Krishnamurti L, Liang J, He Z, Deng Y, Nallagatla V, Hamidi R, Flagg A, Shah N. Incidence and risk factors of pain crisis after hematopoietic cell transplantation for sickle cell disease. Blood Advances 2024, 8: 1908-1919. PMID: 38324722, PMCID: PMC11021890, DOI: 10.1182/bloodadvances.2023010749.Peer-Reviewed Original ResearchCitationsAltmetricConceptsHematopoietic cell transplantationSickle cell diseaseVaso-occlusive episodesPainful crisesCell transplantationPost-HCTGraft failureBefore HCTEvent-free survivalOverall survivalPain syndromePatient agePatient-centered outcomesAlternative donorsIncreased riskCell diseaseRisk factorsNatural historyPatientsLogistic regressionPainTransplantationSurvivalAgeAGVHDImpact of CMV Reactivation on Clinical Outcomes Post Allogeneic Stem Cell Transplant in Patients with Sickle Cell Disease
Rahim M, Ngwube A, Shenkar R, Rohaum H, Rao A, Stanek J, Shah N, Rangarajan H. Impact of CMV Reactivation on Clinical Outcomes Post Allogeneic Stem Cell Transplant in Patients with Sickle Cell Disease. Transplantation And Cellular Therapy 2024, 30: s302. DOI: 10.1016/j.jtct.2023.12.413.Peer-Reviewed Original ResearchConceptsHematopoietic stem cell transplantationImpact of CMV reactivationReduced intensity conditioningSickle cell disease patientsAllogeneic hematopoietic stem cell transplantationSickle cell diseaseStem cell transplantationCMV reactivationMixed chimerismCell transplantationGraft failurePost-allogeneic hematopoietic stem cell transplantationRecovery of absolute lymphocyte countPost allogeneic stem cell transplantationAbsence of CMV-reactivationAllogeneic stem cell transplantationRabbit anti-thymocyte globulinMulti-institutional retrospective studyWhole bloodRisk of graft failureIncidence of GFPre-engraftment periodAnti-thymocyte globulinAbsolute lymphocyte countCompare clinical outcomes
2023
Abatacept-Prophylaxis Based Haploidentical Transplantation May Allow Sustained Engraftment and Offset Gvhd in Non-Malignant Disorders
Ngwube A, Shah N, Schulz G, Krishnamurti L, Shenoy S. Abatacept-Prophylaxis Based Haploidentical Transplantation May Allow Sustained Engraftment and Offset Gvhd in Non-Malignant Disorders. Blood 2023, 142: 4901. DOI: 10.1182/blood-2023-191145.Peer-Reviewed Original ResearchConceptsNon-malignant disordersPost-transplant cyclophosphamideSickle cell diseaseGVHD prophylaxisHematopoietic transplantationEvaluable patientsHaploidentical transplantationImmune suppressionBone marrowFirst year post-HCTGrade 1 acute GVHDChronic GVHD riskChronic skin GVHDGVHD-free survivalPost-transplant lymphoproliferationsRadiation-containing regimensYear post-HCTPhase 2 trialReduced intensity conditioningSerious infectious complicationsSystemic immune suppressionT-cell chimerismAllogeneic hematopoietic transplantationPrimary outcome measureStem cell boost
News
Copy Link
News
- July 26, 2023
2022-23 Department of Pediatrics Faculty Awards
- May 04, 2023
42 Yale Pediatricians Recognized by Connecticut Magazine's 2023 “Top Doctors” List
- May 01, 2023
Connecticut Magazine’s 2023 “Top Doctors” issue recognizes 81 Smilow Cancer Hospital and Yale Cancer Center physicians
- October 12, 2022
Pediatric Bone Marrow Transplant Reunion
Get In Touch
Copy Link
Contacts
Email